Objectives/Hypothesis: Obstructive sleep apnea syndrome is due to pharyngeal obstructions, which can take place at the level of the soft palate. Temperaturecontrolled radiofrequency ablation has been introduced as being capable of reducing soft tissue volume and excessive compliance. The aim of the study was to evaluate prospectively the possible efficacy of temperature-controlled radiofrequency ablation applied to the soft palate in subjects with mild to moderate obstructive sleep apnea syndrome. Study Design: Twenty-nine patients with a respiratory disturbance index between 10 and 30 events per hour, body mass index equal to or less than 30 kg/m 2 , and obstruction at the level of the soft palate were included in a pilot, prospective nonrandomized study. Methods: Snoring and daytime sleepiness were evaluated subjectively. Treatment (maximum of three sessions) was discontinued when the bed partner was satisfied with the snoring level. A full night recording was performed at least 4 months after the last treatment. Results: Mean snoring level decreased significantly from 8.6 ؎ 1.3 to 3.3 ؎ 2.5 on a visual analogue scale (0-10). Daytime sleepiness decreased nonsignificantly. Mean respiratory disturbance index decreased significantly from 19.0 ؎ 6.1 events per hour to 9.8 ؎ 8.6 events per hour. Mean lowest oxygen saturation value increased nonsignificantly from 85.3% ؎ 4.1% to 86.4% ؎ 4.4%. Of the patients, 65.5% were cured of their disease. Conclusions: Temperaturecontrolled radiofrequency ablation was effective in selected patients with mild to moderate obstructive sleep apnea syndrome. A full-night polysomnography is required after completion of treatment to rule out residual disease.
INTRODUCTION
Obstructive sleep apnea syndrome (OSAS) is present in 2% to 4% of the general population. 1 It is associated with excessive daytime sleepiness, snoring, and cardiovascular complications. Obstructive events occur at the level of the pharynx. Obstructions can be diffuse or localized either at the retrolingual site or the retropalatal level. They are due to excessive tissue in a normal skeletal "box," normal-sized tissue in a small squelettal "box," or presence of tissue with excessive compliance.
Several surgical treatments have been advocated to treat OSAS. They are either global, treating the diffuse obstructions with bimaxillary advancement, or more specific, aiming at the soft palate or base of tongue. Uvulopalatopharyngoplasty since 1981 2 and laser assisteduvulopalatopharyngoplasty (LAUP) since 1994 3 have been proposed to treat excessive soft tissue at the level of the soft palate. In 1998, Powell et al. 4 described a new technique using temperature-controlled radiofrequency (TCRF) waves to reduce volume and rigidify it (somnoplasty). When TCRF ablation was applied to the soft palate, there were no severe adverse effects and the uvula's length was reduced. 4, 5 Several other authors have shown that somnoplasty applied to the soft palate of patients with simple snoring, upper airway resistance syndrome, or mild sleep apnea syndrome (with a respiratory disturbance index [RDI] Ͻ15) could reduce snoring, respiratory efforts, and daytime sleepiness. 4, 6 These two studies failed to demonstrate a significant reduction in the number of obstructive events.
Patients with OSAS caused by excessive compliance or tissue hypertrophy, or both, may benefit from radiofrequency ablation. The aim of our study was to evaluate a possible efficacy of radiofrequency ablation with thermal control on selected patients with OSAS on a short-term basis.
PATIENTS AND METHODS
We conducted a pilot, prospective, nonrandomized study at Foch Hospital (Suresnes, France) from October 1998 to March 2001. Patients were physician-referred or self-referred to the Editor's Note: This Manuscript was accepted for publication June 12, 2002 .
Send Correspondence to Frederic Chabolle, MD, Department of Otolaryngology-Head and Neck Surgery, Foch Hospital, 40 rue Worth, 92160 Suresnes, France. E-mail: f.chabolle@hopital-foch.org medical center's otolaryngology clinic. All patients were seeking treatment for habitual snoring or sleep apnea. Patients answered a standard questionnaire including age, sex, weight, height, medical history and past surgery, habitual smoking, or alcohol consumption. A complete otolaryngological examination was performed, including a fiberoptic pharyngoscopy with and without Mü ller maneuver. A sleep study was requested for all patients, either a full polysomnography (level I or II) or a cardiorespiratory recording (level III). Patients who had none (probable simple snoring) or all of the following signs of probable severe sleep apnea syndrome (habitual snoring, daytime sleepiness, apnea witnessed by the bed partner, history of cardiovascular disease, and morbid obesity) were assessed by level III recordings. The other patients were assessed with level I or II polysomnography.
Polysomnographic Methods
Level I polysomnography is defined as a full polysomnographic study in the hospital sleep laboratory. Level II polysomnography is defined as a full polysomnographic study that was performed in an ambulatory setting. Both consisted of recordings of electroencephalogram (C3/A2 and O2/A1 electrodes of the international electrode placement system), electro-oculogram, chin electromyogram, and electrocardiogram. Respiration was monitored by nasal and buccal thermistors until 1999, then with a pneumotachograph for some polysomnographic studies. Airflow and thoracoabdominal movements were monitored to distinguish between central and obstructive breathing disorders. Oxygen saturation was recorded by means of pulse oximetry. Level III polysomnography is an ambulatory study measuring nasal and oral airflow, chest wall impedance, oxygen saturation, and heart rate.
An apneic event was defined as cessation of airflow for at least 10 seconds. A hypopneic event was defined as a decrease in airflow of greater than 50%, associated with a drop in oxygen saturation greater than 3% and/or a microarousal (when level I or II polysomnography was performed). Sleep studies were scored for presence of apnea, hypopnea, and changes in oxygen saturation. Sleep-wake state and arousals were scored in polysomnography level I and II using previously published data. 7, 8 Indications for treatment of mild to moderate obstructive sleep apnea followed a specific decision tree. All patients were advised on behavior modifications (loss of weight, avoidance of tobacco or alcohol, anxiolytic consumption, or a combination of these), dental appliances, and continuous positive airway pressure. If these measures were refused or had been attempted previously, three surgical treatment options on the soft palate could be offered: TCRF ablation, LAUP, or uvulopalatopharyngoplasty (UPPP). These surgical options were offered only if the patients fulfilled the following elements: an RDI between 10 and 30 events per hour, airway obstruction visualized clinically and during the Mü ller maneuver primarily at the level of the soft palate, and no morbid obesity, as defined by a body mass index (BMI) greater than 30 kg/m 2 . On a routine basis, recommendations were made by the physician toward one of the three treatment options based on the decision tree. Uvulopalatopharyngoplasty was recommended in case of tonsil hypertrophy or a nasal obstruction linked to a septal deformation (or both). Laser assisted-uvulopalatopharyngoplasty was recommended in case of a long uvula, moderate tonsil hypertrophy, or the presence of nasal obstruction linked to inferior turbinate hypertrophy (or a combination of these). Temperaturecontrolled radiofrequency ablation was recommended in case of absence of moderate to major tonsil hypertrophy or if nasal obstruction linked to inferior turbinate hypertrophy was present (or both). The final therapeutical option was chosen after reviewing results, possible side effects, and complication rates of each of the treatment options with the patient. Information consent was obtained from each patient.
The inclusion/exclusion criteria of the present study were stringed and were as follows: TCRF procedure on the soft palate alone, no or mild nasal obstruction complaint, no history of surgery on the soft palate, no active upper airway infection or blood coagulation abnormalities, and a follow-up clinical examination and sleep study.
Procedures and Postoperative TemperatureControlled Radiofrequency Evaluation
All procedures were performed by two physicians. Each patient received local anesthesia; Xylocaine was first sprayed on the tongue and oral cavity. After this, 2 to 10 mL 1% lidocaine with 1:100,000 epinephrine was injected at the sites of treatment. The procedures were performed in a surgical room in an ambulatory mode.
Somnoplasty Procedure
The equipment used included, first, a 215 radiofrequency control unit (Somnus Medical Technologies Inc., Sunnyvale, CA) and, second, an S2 radiofrequency control unit (Somnus Medical Technologies Inc.) connected to a sterile, single-use handpiece, consisting of an electrode with a total length of 2.0 cm (with 1 cm active and 1 cm insulated). Two thermocouples, one at the tip of the electrode and one at the insulation, continuously monitor temperature and impedance during electrode penetration and treatment. A dispersive electrode was applied to the patient's back to return current to the control unit.
Maximum power was set at 10 W. Maximum target temperature was 85°C. Three protocols using different levels of energy were successively used in time: total energy per session of 1300 J with three lesions (protocol 1, from October 1998 to December 1998), 2800 J with four lesions (protocol 2, from January 1999 to June 1999) and 2100 J with three lesions (protocol 3, from July 1999 to December 2000) (Fig. 1) . The last polysomnographic studies were performed in March 2001. Levels of energy were not based on the soft palate aspect (thickness, length of the uvula). They were part of a search for the appropriate level of energy. Energy delivery during the session was stopped if pain or blanching of the mucosa occurred. The precise energy delivered was recorded. No uvulectomies were performed.
A soft diet was recommended for 2 days after treatment. Paracetamol was prescribed in case of discomfort or pain. Steroids (prednisone, 20 mg/tablet) were prescribed at the dosage of 1 mg/kg for 1 day or more if "a swelling sensation in the back of the throat" was noted.
Evaluation
Evaluation of efficacy of somnoplasty was assessed subjectively by the patient and the patient's bed partner and objectively by a polysomnographic study (level I, II, or III).
Subjective evaluation. The bed partner evaluated the snoring volume on a visual analogue scale (VAS) ranging from 0 (no snoring) to 10 (snoring loud enough to be heard from another room or the bed partner has to leave the room to sleep elsewhere). 4 On the VAS, levels of 1 to 3 were considered loud respiration; 4 to 6, moderate snoring; 7 to 8, loud snoring; and 9 or 10, very loud snoring. Satisfaction of the bed partner was also assessed.
The patient evaluated his or her somnolence on the standardized Epworth Sleepiness scale. Absence of daytime sleepiness was defined as a score equal to or less than 8.
Subjective evaluation of snoring and sleepiness using the same scales took place before treatment and was scheduled for 6 to 8 weeks after each treatment session. A clinical examination of the soft palate was performed 6 to 8 weeks after the treatment session, determining the presence of any mucosal/uvula lesions. This examination could occur earlier if the patient felt a severe pain despite analgesic intake for more than 2 days.
Objective evaluation. Respiratory parameters (apnea and hypopnea index, minimum oxygen saturation) were assessed by a level I, II, or III polysomnographic study. Objective evaluation took place at least 4 months after the last treatment session. The last treatment session was defined arbitrarily as the session when 1) the bed partner was satisfied with the snoring volume after TCRF ablation, the snoring not being disturbing anymore, or 2) the bed partner was not satisfied with the snoring volume after TCRF ablation and the patient wished to stop TCRF treatment or change to another treatment (LAUP).
No more than three treatment sessions were performed, with an interval of 6 to 8 weeks between each treatment session. The patients were advised that they would probably need two or three treatment sessions.
The level of postoperative polysomnography (I, II, or III) was chosen regarding the success on snoring and daytime sleepiness. If treatment was effective on snoring but not on somnolence, a level I or II polysomnographic study was prescribed; nevertheless, if level I or II polysomnography was not available at the moment of necessary recording, a level III polysomnographic study was performed.
Criteria for Success and Statistical Analysis
Success on snoring was defined by a final snoring score on VAS of 3 or less and a satisfied bed partner. Improvement was defined as a final snoring volume lower than preoperative.
Cure of sleep apnea was defined as an RDI below 10 events per hour. Temperature-controlled radiofrequency was considered an effective treatment if the RDI after TCRF ablation was less than 20 events per hour with a reduction greater than 50% from the baseline RDI.
All results are expressed as the mean Ϯ SD. Data were analyzed (Statview for Windows, version 5.0, SAS Institute Inc.) using a Student paired t test. Linear regression was used to appreciate the relationship between different parameters. A P value less than .05 was considered significant.
RESULTS
One hundred fifty-five patients with obstructive sleep apnea fulfilled our criteria of a possible surgical procedure on the soft palate and accepted to go to "surgery." Fortyseven patients elected to undergo UPPP; 30 patients, LAUP; and 78 patients, TCRF. Among the 78 patients, 37 did not come back after the first treatment session or for a second treatment session. Forty-three patients had a full course of treatment (i.e., were evaluated clinically after the last treatment session as we defined it previously). Four of them had a simultaneous treatment at two sites: soft palate and inferior turbinates. They were not included in the study.
Twenty-nine patients (26 males and 3 female patients) completed the study clinically and with posttreatment polysomnography. Mean clinical and polysomnographic follow-up times, respectively, were 11.0 Ϯ 4.7 weeks and 8.5 Ϯ 3.8 months after the last procedure. Mean age and BMI were 57.4 Ϯ 9.2 years and 25.7 Ϯ 2.7 kg/m 2 , respectively. Two patients were treated with protocol 1, 11 with protocol 2, and 16 with protocol 3. Mean number of sessions was, in protocol 1, 2.5 Ϯ 0.7; in protocol 2, 2.0 Ϯ 0.6; and in protocol 3, 2.1 Ϯ 0.7. Mean total energy delivery per session was, in protocol 1, 1387 Ϯ 62 J; in protocol 2, 2719 Ϯ 106 J; and in protocol 3, 2170 Ϯ 100 J. Mean BMI after TCRF ablation was not significantly different from baseline (P ϭ .5). Results are presented pooled in terms of energy delivery because of the small number of patients treated in protocol 1.
Snoring improved in 96.6% of the patients (28 of 29). In none of the patients did snoring get worse. Mean snoring level decreased significantly from 8.6 Ϯ 1.3 to 3.3 Ϯ 2.5 (P Ͻ.0001), and 86.2% of the bed partners were satisfied. Success of the treatment on snoring based on a VAS score of 3 or less and a satisfied bed partner was 65.5%.
Daytime sleepiness based on Epworth Sleepiness scale score improved in 62.1% of the patients (18 of 29). Mean Epworth Sleepiness scale score decreased nonsignificantly from 7.3 Ϯ 3.6 to 6.3 Ϯ 3.9 (P ϭ .15). Daytime sleepiness with an Epworth Sleepiness scale score greater than 10 was found in 20.7% (6 of 29) of the patients.
The level of polysomnography before or after TCRF ablation did not seem to influence the outcome. The level of polysomnography before or after TCRF ablation for each patient is shown in Figure 2 .
Mean apnea and hypopnea indexes before and after TCRF ablation are shown in Figure 3 Among the 19 patients who were cured, 4 patients remained sleepy according to their Epworth Sleepiness scale scores. These four patients had a high number of microarousals (25 Ϯ 16.7 microarousals per hour of sleep) on the polysomnography after TCRF ablation. In one patient, the abnormal level of microarousals was related to periodic limb movements. In the other three patients, these microarousals might have been related to limitation flow. Mean minimal oxygen saturation increased nonsignificantly from 85.3% Ϯ 4.1% to 86.4 Ϯ 4.4% (P ϭ .35).
No patients complained of any respiratory distress, hemorrhage, or cardiovascular complications in the postoperative period. Three soft palate perforations occurred in protocol 2, with spontaneous healing in two cases. The third patient had a persistent hole of 5 mm in diameter, which gave a whistling sound to his respiration during sleep. No uvula necrosis was observed.
Body mass index, age, length of the uvula, thickness of the soft palate on clinical examination, dental class, Epworth Sleepiness scale score, snoring volume, and severity of OSAS by the RDI did not correlate with the outcome.
DISCUSSION
The main goal of the present study was to evaluate a possible efficacy of radiofrequency ablation with thermal control applied on the soft palate of selected patients with mild to moderate sleep apnea. The main finding of the present study is that in selected patients, TCRF ablation can significantly reduce the RDI in subjects with OSAS.
This decrease is associated with a significant decrease of the snoring volume.
The definitions of cure and success rate were taken from the international literature. In most of the sleep institutions, OSAS is defined by an RDI greater than 10 events per hour. Therefore, cure of OSAS occurs when the patient's RDI is less than 10. Most of the reports have defined "success" as a reduction of preoperative RDI of more than 50% and a postoperative RDI less than 20. 9 The term "success" being closer to the term "cure," we chose to define this state as the treatment efficacy.
Uvulopalatopharyngoplasty is the only soft palate surgical technique recommended by the American Sleep Disorders Association because of its demonstrated efficacy on OSAS. 10 In particular, the efficacy rate of UPPP was evaluated in the meta-analysis of Sher et al. 9 It was estimated to be 40.7%. Studies included in the meta-analysis of Sher et al. 9 often aimed at efficacy and did not always take into account all the specific outcome predictive factors. Indeed, in the meta-analysis of Sher et al., 9 as well as in other publications, several factors were shown to give poorer results, especially in subjects with higher BMI, 11 nontreated sites of obstruction and severe OSAS.
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Although Sher et al. 9 and other authors 12, 13 did not find any significant difference in BMI between UPPP success and failure, some authors, such as Chabolle et al., 11 showed that a BMI exceeding 27 kg/m 2 gave poorer results. Indeed, obesity can be responsible for UPPP failures because of factors that are not addressed by surgery: compromised respiration (overlap syndrome) 16 and excess compliance. 17 Fat can also infiltrate pharyngeal tissue. When fat is located around the pharynx, 18 it is inaccessible by UPPP.
Site of obstruction can be assessed by several means, such as fiberoptic awake endoscopy with or without Mü ller maneuver, airway manometry, asleep endoscopy with or without continuous positive airway pressure, or imaging. Although some techniques greatly improve UPPP outcome, they are difficult to use in standard clinical practice.
14 There is no universally validated method to determine precisely the site of obstruction. The methods recommended by Sher et al. 9 are fiberoptic endoscopy and lateral cephalometry. Lateral radiographic cephalometrics, although performed with the patient awake and seated upright, and best for bony structures and not for airway spaces or tissue volume, may give information regarding the site of obstruction. A retrolingual site of obstruction may be pointed out by a low position of the hyoid bone and by a narrowed posterior airway space secondary to a large tongue or retrognathia. A retrovelar site of obstruction could be pointed out by an increased uvula length. Millman et al. 12 showed that a lower position of the hyoid bone and presence of retrognathia could greatly decrease the likelihood of a positive outcome. Woodson and Conley 15 showed that in retrognathic patients, the presence of a small posterior airway space and position of the hyoid bone were negative outcome predictive factors. Doghramji et al. 19 showed that success tended to be greater when uvula length was longer.
It seems obvious that determination of the site of obstruction is crucial when deciding a site-specific surgical procedure. In fact, Sher et al. 9 showed that patients with a retrovelar site of obstruction (type I obstruction) had a 52.3% success rate compared with 5.3% for patients with a combined site of obstruction (tongue and soft palate [type II obstruction]) or a tongue base obstruction (type III obstruction). Site of obstruction also seems to be linked to the number of obstructive events. Sher et al. 9 showed that the RDI and, even more, the apnea index, were greater when comparing patients with type I obstruction versus those with types II and III obstruction.
Severity of OSAS probably should be taken into account, especially since Sher et al. 9 showed that responders (RDI of less than 20 and a 50% decrease from preoperative RDI) had a lower baseline (43.1 Ϯ 26.3 vs. 65.7 Ϯ 26.7). Chabolle et al. 11 found a cut-off point at 30 events per hour of sleep. Cure rate was 80% when the RDI was less than 20 as opposed to 27% when it was greater than 30 events per hour.
The patients in the present study were selected according to stringent criteria: soft palate as the site of obstruction, a BMI less than 30 kg/m 2 , and an RDI of less than 30 events per hour. The treatment failures in the present study may have had an associated tongue base obstruction during the night, although it was not observed during clinical examination, even with Mü ller maneuver. A cephalometric analysis may have been useful to determine whether the subject had a possible tongue base obstruction. The treatment failures may have also been due to residual excessive tissue in the soft palate. Radiofrequency ablation has been shown to reduce tongue tissue in animals. 20 On the human soft palate, using a mean total energy level of 2377 J in one to several sites, a reduction of volume was shown by Powell et al. 4 Shrinkage in uvula length, but not in width, was observed. This shrinkage may be attributed to the scarring process, which is thought to rigidify the soft palate and decreases excessive compliance. Reduction of volume by necrosis may only be obtained using higher levels of energies. This may not be possible because of potential side effects such as postoperative edema, which may compromise the airway, and mucosa necrosis, which may lead to perforation or uvula destruction. Therefore, using lower energies may provide only a nonsignificant volume reduction by necrosis, a probable volume reduction by retraction, and a decrease in compliance. Although not significant in our study, a long uvula should probably not, for the reasons mentioned earlier, be the best indication for radiofrequency ablation in OSAS.
The time to stop treating a patient is another possible factor that might have lowered one or the other, success rate and/or cure rate. Our protocol stated that treatment should be stopped when the subject's bed partner was satisfied with the snoring level. This evaluation is highly subjective. Post-treatment snoring levels on the VAS were greater for patients who were considered failures with TCRF ablation. This may mean that treatment was insufficient and the patient may require more sessions. Because of the high cost of the electrodes and a probable treatment of all the soft palate areas possible with TCRF ablation, we limited the number of sessions to three and proposed another therapeutic option.
Snoring is not the best method to determine when to stop treatment because some bed partners were satisfied with the snoring level even though the patients were not cured of their disease; on another hand, some patients, who did not have any significant residual apnea or hypopnea, continued to snore and remained somnolent. Ambulatory oxygen saturation, because of it lower cost and its ease of use, could be one possible tool for evaluation of when to stop the treatment.
A polysomnographic study should be performed in all treated patients. It detects TCRF ablation failures or worsening after treatment. Four patients in our study got worse. Several hypotheses can be made, including occurrence of incidental factors such as sleep deprivation or acute nasal obstruction during the night of the recording or the presence of a new site of obstruction at the level of the tongue base. Critical closing pressure may have been higher in the first place at the level of the soft palate than at the level of the tongue base. After TCRF treatment and a possible lowering of the critical closing pressure at the level of the soft palate, the tongue base may have become the primary site of obstruction. 21, 22 Patients were not highly somnolent at baseline because their mean Epworth sleepiness scale score before TCRF ablation was what is considered normal (7.3 Ϯ 3.5). Six of 29 patients (20.7%) patients had an Epworth sleepiness scale score greater than 10 after TCRF ablation.
Among them, four patients, who all had an initial RDI greater than 13 events per hour of sleep, were cured of their OSAS based on polysomnography results following our criteria. One cases was clearly related to periodic limb movements. Three of four patients showed an abnormal number of microarousals, which might have been related to respiratory limitation flow. One hypothesis is that TCRF ablation may have transformed OSAS in upper airway resistance syndrome by changing the soft palate's compliance. The compliance was such that the soft palate no longer collapsed against the posterior pharyngeal wall but increased pharyngeal pressures remained. This hypothesis must be confirmed by a study of OSAS patients with a full-night polysomnographic recording with esophageal pressure measurement before and after TCRF treatment.
CONCLUSION
The soft palate is involved in the constitution of a pharyngeal obstruction in obstructive sleep apnea. In some cases, it could be the only site or the predominant site of obstruction. If patients are not overweight and do not have severe OSAS, palate surgery can have a fairly high success rate. We have shown that radiofrequency ablation with thermal control could, in a small, clinically selected population, have a 65.5% cure rate. Clinical teams should extend the present study to a greater number of patients and on a long-term basis to possibly place radiofrequency ablation as one of the treatment of choice for some patients with mild to moderate obstructive sleep apnea, with the advantage of it being associated with few side effects.
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